Xbrane Raises Millions More As It Eyes Ranibizumab Filings
More Than 2.8 Million New Shares Issued
With ambitions to file biosimilar ranibizumab and initiate one new development program per year, Sweden’s Xbrane Biopharma has brought in millions of much needed fresh capital to fuel operations.
